Current Therapeutic Strategies for Glioblastoma
نویسندگان
چکیده
منابع مشابه
Glioblastoma under Siege: An Overview of Current Therapeutic Strategies
Glioblastoma is known to be one of the most lethal and untreatable human tumors. Surgery and radiotherapy in combination with classical alkylating agents such as temozolomide offer little hope to escape a poor prognosis. For these reasons, enormous efforts are currently devoted to refine in vivo and in vitro models with the specific goal of finding new molecular aberrant pathways, suitable to b...
متن کاملHemangiomas - current therapeutic strategies.
Hemangiomas are benign neoplasms of the vasculature frequently encountered in children. Several studies have shown that these tumors are characterized by excessive angiogenesis. Although benign, the lesions can present with complications, and may thus require treatment. There are multiple therapeutic options available for patients with problematic or life threatening hemangiomas, some of which ...
متن کاملCurrent Therapeutic Strategies for Human Usher Syndrome
The human Usher syndrome (USH) is the most frequent cause of combined deafblindness in man. It is clinically and genetically heterogeneous and at least twelve chromosomal loci are assigned to three clinical USH types. USH1, USH2 and USH3 differ in the severity of the symptoms: hearing loss, balance problems and retinal degeneration namely retinitis pigmentosa (RP), as well as in the progression...
متن کاملCurrent therapeutic strategies in glomerulonephritis.
Over the past 20 years the therapy of glomerulonephritis (GN) has evolved. Today apart from steroids and cyclophosphamide, newer agents like cyclopsorine A and tracrolimus (FK 506) have been reported to achieve remission (partial or complete) in patients with nephrotic syndrome due to various GN which have failed to respond to steroids and cyclophosphamide. For those patients who do not respond...
متن کاملCurrent role of anti-angiogenic strategies for glioblastoma.
OPINION STATEMENT Glioblastoma, an incurable, malignant, and highly vascular tumor, is a seemingly ideal target for anti-angiogenic therapies such as bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody. Phase II trials in recurrent glioblastoma demonstrated bevacizumab was associated with clinical benefits, including decreases in brain edema and corticosteroids us...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Brain Sciences
سال: 2019
ISSN: 2076-3425
DOI: 10.3390/brainsci10010015